Kimberly-Clark
KMB
$98.84
+0.89%
Kimberly-Clark Corp. is a leading global manufacturer of essential consumer products, operating primarily in the Household & Personal Products industry with a portfolio of iconic brands including Huggies, Kleenex, Cottonelle, and Kotex. The company is a dominant market leader in the tissue and hygiene realm, deriving over half its sales from personal care and a third from consumer tissue, with a distinct competitive identity built on strong brand equity and a vast global distribution network. The current investor narrative is dominated by its pending acquisition of Kenvue's consumer health portfolio in the second half of 2026, a major strategic move aimed at portfolio diversification, while the stock is also being debated as a potential value and high-yield opportunity following a significant price decline over the past year.…
KMB
Kimberly-Clark
$98.84
Related headlines
Investment Opinion: Should I buy KMB Today?
Rating: Hold. The core thesis is that KMB presents a high-yield, deep-value opportunity for extremely patient investors, but near-term fundamental headwinds and acquisition overhang warrant caution, making it unsuitable for new capital except for those with a very long horizon and high risk tolerance regarding its leverage.
Supporting evidence includes a forward PE of 12.95x, which is below typical consumer staples valuations and implies depressed expectations. The dividend yield of 4.94% is attractive and supported by strong FCF of $2.38B, though the high payout ratio of 82.14% leaves little margin for error. However, these positives are counterbalanced by a 17.21% YoY revenue decline in Q4 and a dangerously high debt-to-equity ratio of 4.77. Analyst sentiment is neutral-to-negative, with limited coverage, offering no clear catalyst for a re-rating.
The thesis would upgrade to a Buy if revenue growth stabilizes (turns positive or shows sequential improvement) and the forward PE compresses further toward 11x, offering a greater margin of safety. It would downgrade to a Sell if the dividend payout ratio exceeds 95%, the stock breaks decisively below its 52-week low of $92.42 on high volume, or details emerge suggesting the Kenvue acquisition will be excessively dilutive or debt-funded. Relative to its own history and the sector, the stock is fairly valued to slightly undervalued on earnings but carries a premium of risk due to its leverage and growth challenges.
Sign up to view all
KMB 12-Month Price Forecast
KMB is a stalled defensive stalwart with a valuable income stream but significant operational and financial challenges. The neutral stance reflects the offsetting forces of deep value and high yield against persistent revenue declines and leveraged balance sheet risk. The path of least resistance is sideways consolidation (base case, 60% probability) as the market awaits clarity on core business stabilization and the Kenvue acquisition. The stance would upgrade to bullish on evidence of sustained revenue stabilization and prudent acquisition financing. It would turn bearish on a breakdown below $92.42, a dividend coverage ratio deteriorating towards 100%, or a clear indication that the Kenvue deal will be overly dilutive.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $128.49 and implied upside of +30.0% versus the current price.
Average Target
$128.49
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$79 - $128
Analyst target range
Analyst coverage for KMB is currently very limited, with only 2 analysts providing estimates, indicating insufficient coverage for a robust consensus view; this limited coverage, for a company of its size and history, may reflect diminished institutional interest or a wait-and-see approach ahead of the major Kenvue acquisition, leading to higher potential for price dislocation and less efficient price discovery. The available data shows a wide range in estimates, with projected EPS for the coming year between $8.95 and $9.99, and revenue estimates between $26.77 billion and $29.16 billion; this wide spread signals high uncertainty among the few covering analysts regarding the company's near-term trajectory, likely tied to execution risks on the acquisition and the volatile consumer spending backdrop. Recent institutional rating actions have been predominantly neutral or negative, with firms like Citigroup maintaining a Sell and Deutsche Bank a Hold, though Piper Sandler maintains an Overweight rating; the lack of a clear bullish consensus and the prevalence of Hold/Sell ratings align with the stock's weak price performance and the challenging fundamental outlook.
Bulls vs Bears: KMB Investment Factors
The investment debate for KMB is a classic battle between deep value and deteriorating fundamentals. The bear case currently holds stronger evidence, anchored by a severe revenue decline of -17.21% YoY, high financial leverage (D/E of 4.77), and a sustained technical downtrend. The bull case rests on valuation near historical lows (forward PE of 12.95x), a high covered dividend yield (4.94%), and the long-term optionality of the Kenvue acquisition. The single most important tension is whether the company's strong cash flow and defensive brand portfolio can stabilize operations and justify its high leverage before the acquisition-related risks materialize, or if the revenue decline signifies a deeper, secular challenge that the dividend cannot offset.
Bullish
- Deep Value at Historical Lows: The stock trades at a trailing PE of 16.63x and a forward PE of 12.95x, near the lower end of its historical range. With the price at $98.84, just 7% above the 52-week low of $92.42, the market has priced in significant pessimism, offering a margin of safety.
- Strong Free Cash Flow & High Dividend: The company generates robust free cash flow of $2.38 billion TTM, which supports its generous 4.94% dividend yield. The payout ratio of 82.14% is high but covered by cash generation, providing income appeal.
- Strategic Kenvue Acquisition Potential: The pending acquisition of Kenvue's consumer health portfolio in H2 2026 is a major strategic move for portfolio diversification. If executed well, it could provide a new growth vector for the mature business.
- Defensive Profile with Low Beta: KMB's beta of 0.296 indicates it is approximately 70% less volatile than the market, a classic trait of a defensive consumer staples stock. This should provide relative stability in market downturns.
Bearish
- Severe Revenue Contraction: Q4 2025 revenue of $4.08B declined 17.21% YoY, following a sequential decline from Q3. This persistent top-line pressure, likely from volume softness and pricing normalization, is a core fundamental weakness.
- High Financial Leverage: The debt-to-equity ratio of 4.77 is exceptionally high, elevating financial risk, especially in a higher interest rate environment. This leverage complicates the upcoming Kenvue acquisition.
- Weak Technical & Sentiment Damage: The stock is in a severe downtrend, down 30.79% over the past year and 18.61% over six months. It has starkly underperformed the SPY by -65.69% over one year, reflecting deep negative sentiment.
- Limited Analyst Coverage & Uncertainty: Only 2 analysts provide estimates, indicating low institutional interest and high uncertainty. The wide EPS estimate range ($8.95 to $9.99) and prevalence of Hold/Sell ratings underscore the lack of conviction.
KMB Technical Analysis
The stock is in a pronounced and sustained downtrend, evidenced by a 1-year price change of -30.79% and a 6-month decline of -18.61%. With a current price of $98.84, it is trading at approximately 46% of its 52-week range ($92.42 to $144.31), positioning it much closer to its 52-week low than its high, which suggests a deep value opportunity but also reflects significant fundamental and technical damage that must be respected. Recent short-term momentum shows a slight divergence, with a 1-month gain of 0.12% against the severe longer-term downtrend, while the 3-month performance remains negative at -0.48%; this minor stabilization over the past month could indicate a potential basing pattern or a temporary pause before further declines, especially given its stark underperformance relative to the SPY, which is up 7.36% over the same 1-month period. Key technical support is clearly defined at the 52-week low of $92.42, while resistance sits at the 52-week high of $144.31; a decisive breakdown below $92.42 would signal a continuation of the bearish trend, whereas a sustained move above the recent recovery high near $111.44 would be needed to suggest a meaningful reversal. The stock's low beta of 0.296 indicates it is approximately 70% less volatile than the broader market, which is typical for a defensive consumer staples name but also means it has offered little protection during its own steep decline.
Beta
0.30
0.30x market volatility
Max Drawdown
-35.9%
Largest decline past year
52-Week Range
$92-$144
Price range past year
Annual Return
-30.8%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | +0.1% | +9.5% |
| 3m | -0.5% | +2.7% |
| 6m | -18.6% | +5.8% |
| 1y | -30.8% | +34.9% |
| ytd | -2.5% | +4.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Revenue growth has been weak to negative, with the most recent Q4 2025 revenue of $4.08 billion representing a year-over-year decline of -17.21%; this follows a sequential decline from Q3's $4.13 billion, indicating persistent top-line pressure likely from volume softness, pricing normalization, and foreign exchange headwinds in a challenging consumer environment. The company remains profitable, posting Q4 net income of $499 million, but profitability metrics show pressure with a gross margin of 35.91% and a net margin of 12.23%; comparing to the prior-year Q4, the net margin has improved from 9.07%, suggesting some cost discipline, but the gross margin of 35.91% is down from the 35.99% reported in Q4 2024, highlighting ongoing input cost challenges. The balance sheet carries significant financial leverage with a debt-to-equity ratio of 4.77, which is high and elevates risk in a rising rate environment; however, the company generates substantial cash flow, with trailing twelve-month free cash flow of $2.38 billion, providing coverage for its generous dividend (payout ratio of 82.14%) and some capacity for strategic moves like the planned Kenvue acquisition, though the current ratio of 0.75 indicates potential liquidity strain in covering short-term obligations.
Quarterly Revenue
$4.1B
2025-12
Revenue YoY Growth
-0.17%
YoY Comparison
Gross Margin
+0.35%
Latest Quarter
Free Cash Flow
$2.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 16.63x and a forward PE of 12.95x based on analyst estimates; the forward multiple being lower than the trailing multiple implies the market expects earnings growth, with the forward PE embedding expectations for the estimated EPS of $9.11. Compared to sector averages, the valuation appears mixed: the trailing PE of 16.63x is below the typical range for high-quality consumer staples, while the Price-to-Sales (PS) ratio of 1.95x and EV/Sales of 2.40x suggest the market is applying a discount to sales, likely reflecting the recent revenue declines and modest growth prospects outside of acquisitions. Historically, the current trailing PE of 16.63x sits near the lower end of its own historical range observed over recent quarters, which has seen PEs fluctuate from the low teens to over 20x; trading near historical lows suggests the market is pricing in pessimistic expectations, potentially offering a margin of safety if the company can stabilize its fundamentals and successfully integrate the Kenvue assets.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~114x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. The company carries a high debt-to-equity ratio of 4.77, which strains the balance sheet ahead of a major acquisition. While free cash flow of $2.38B is strong, a current ratio of 0.75 indicates potential liquidity strain in covering short-term obligations. The core business is under significant pressure, with Q4 revenue declining 17.21% year-over-year, raising questions about the sustainability of earnings needed to service debt and fund the dividend, which already has an 82.14% payout ratio.
Market & Competitive Risks center on valuation compression and execution uncertainty. The stock has a max drawdown of -35.92% from its recent high, reflecting the market's harsh repricing of a former staple. Its low beta of 0.296 did not protect it from this idiosyncratic decline. The primary external threat is the successful integration of the Kenvue acquisition, slated for late 2026; recent news highlights Kenvue's own struggles with litigation and analyst downgrades, complicating the deal's perceived value. Furthermore, trading at a forward PE of 12.95x, any failure to meet earnings estimates could trigger further multiple contraction.
Worst-Case Scenario involves a perfect storm of continued revenue erosion, rising interest expenses on its high debt load, and a botched or overpriced Kenvue acquisition. This could lead to a dividend cut—a catastrophic event for its income-focused shareholder base—and a severe derating. The realistic downside is to the 52-week low of $92.42, representing a -6.5% decline from the current price of $98.84. A breach of that support could see a fall towards the $85-$90 range, implying a total potential loss of 10-15% in an adverse scenario, not accounting for a full-scale crisis of confidence.
FAQ
The key risks are, in order of severity: 1) Financial Risk: Exceptionally high debt-to-equity of 4.77 increases vulnerability to rising rates and limits financial flexibility. 2) Operational Risk: Persistent revenue decline, evidenced by a -17.21% YoY drop in Q4, threatens earnings stability and dividend coverage. 3) Execution Risk: The pending Kenvue acquisition is complex, costly, and carries significant integration and financing uncertainty. 4) Sentiment Risk: The stock has underperformed the SPY by -65.69% over one year, indicating deeply negative momentum that could persist regardless of fundamentals.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $100 and $110, as revenue pressures moderate but the Kenvue deal keeps a lid on upside. The Bull Case (25% probability) projects a range of $115 to $125 if business stabilizes and acquisition sentiment turns positive. The Bear Case (15% probability) warns of a drop to $85-$92 if earnings disappoint or dividend fears escalate. The base case is most likely, hinging on the assumption that free cash flow remains strong enough to maintain the dividend despite top-line weakness.
KMB appears fairly valued to slightly undervalued based on earnings multiples but overvalued when considering its growth profile and financial risk. Its forward PE of 12.95x is below typical consumer staples averages, suggesting the market is discounting its challenges. However, the high Price-to-Book ratio of 22.37 reflects significant intangible asset value (brands) and financial leverage. The valuation implies the market expects minimal growth and is primarily valuing the stock for its dividend, with a large discount applied for execution and balance sheet risks.
KMB is a speculative buy only for a specific type of investor. For income-focused investors with a very long-term horizon (5+ years) and high risk tolerance regarding balance sheet leverage, the 4.94% yield and valuation near historical lows (forward PE of 12.95x) may be appealing. However, given the severe revenue decline of -17.21%, high debt-to-equity ratio of 4.77, and uncertain major acquisition ahead, it carries significant fundamental risk. Most investors should adopt a Hold stance, awaiting clearer signs of operational stabilization.
KMB is strictly a long-term investment, with a suggested minimum holding period of 3-5 years. Its low beta of 0.296 makes it unsuitable for short-term trading, as it lacks volatility and momentum. The investment thesis relies on the patient collection of its 4.94% dividend while awaiting a potential operational turnaround or successful Kenvue integration years down the line. Short-term traders would find better opportunities elsewhere, given the stock's entrenched downtrend and lack of near-term catalysts.
